NEW YORK (GenomeWeb News) – Pacific Biomarkers will provide access to its validated biomarker assays to WuXi PharmaTech under a collaboration announced today.

As part of the deal, Pacific Biomarkers will provide its biomarkers to support Shanghai-based WuXi's integrated clinical trial testing services, including bioanalysis and central laboratory services for drugmakers and biotech firms doing clinical drug development in China.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.

Sponsored by

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.